Understanding Hepatitis B and Its Risks

Hepatitis B (HBV) is a serious viral infection that can lead to cirrhosis, liver cancer, and ultimately liver failure. Infants and children who contract HBV are far more likely than adults to develop chronic, lifelong infection with these severe consequences.¹

Unlike many communicable diseases, HBV does not spread through coughing or sneezing, but through blood exposure. Higher-risk situations include unprotected sex, sharing needles, or any contact with infected blood. Infants face elevated risk when born to an infected parent or when exposed through breaks in the skin.² Socioeconomic differences also matter; individuals from lower-income households face a 28% higher risk of infection.³

ACIP Reverses Universal Infant Vaccination Recommendation

On December 5, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted 8–3 to reverse the long-standing policy of universal HBV vaccination at birth, instead recommending individual, provider–parent decision-making.⁴

The vote followed presentations emphasizing improvements in blood screening, dialysis safety, and needle-exchange programs. ACIP also reviewed a 2019 study showing that only 0.5% of U.S. pregnancies (1 in 200) involve a parent who tests positive for hepatitis B surface antigen, and that 57.9% (1 in 2) of these births are to individuals from high-endemic countries.

Why Universal Vaccination Was Adopted in 1991

In 1991 ACIP examined these issues from an acute, comprehensive angle. The Committee concluded that pre-vaccination risk-based screening alone failed to identify a large proportion of HBV-positive cases.⁵ Infants and children under age five typically show no symptoms, making missed diagnoses common.

The evidence was compelling:

• Infants infected perinatally have up to a 90% chance of developing chronic HBV.
• Chronic HBV leads to liver failure, liver cancer, and premature death.

Therefore, ACIP recommended administering the first HBV vaccine dose at birth.

This universal birth-dose policy was extraordinarily successful:

• HBV infection among children and adolescents dropped 99% between 1991 and 2019.⁵
• The policy prevented over 500,000 childhood infections and more than 90,000 deaths.

As Dean Kelly Gebo of the George Washington University Milken Institute School of Public Health stated, “It has all but eliminated chronic HBV in children”.⁵

American Public Health Association (APHA) Executive Director Dr. Georges C. Benjamin added, “There is absolutely no evidence suggesting the highly successful policy needs to be revisited. The science is clear.”

Concerns About the New Policy

Now, with a national policy that diametrically reverses three decades of public health success, the United States is poised—whether intentionally or not—to conduct a natural experiment. Over the coming decade, outcomes under individualized decision-making will be compared to those achieved through universal vaccination.

A public comment submitted by APHA and 73 public health deans and scholars strongly urged ACIP to maintain universal birth-dose vaccination, arguing that the evidence overwhelmingly supports maintaining the existing position. The Michigan Department of Health and Human Services,⁶ American Academy of Pediatrics,⁷ and American Academy of Family Physicians⁸ have adopted similar stances.

The Ecological Fallacy: A Potential Misstep

Public health students learn that ecological studies can mislead, especially when national or group-level trends are used to guide decisions about individual risk.⁹ By comparing U.S. HBV policy to countries without universal vaccination, ACIP may be committing this error.

For example:

• Over 50,000 U.S. births occur in emergency departments each year, where maternal records—including HBV status—are often unavailable.
• Many individuals delivering in emergency settings have higher socioeconomic risks and lower access to prenatal care.
• These infants may now miss the HBV vaccine at birth and later rely on strained Medicaid or Vaccines for Children (VFC) programs.

These are precisely the families most vulnerable to gaps in individualized vaccination decisions made under the umbrella of the new federal recommendations.

Why Infants Are at Highest Risk

Mother-to-child transmission remains the primary pathway for infant HBV infection. Additional risks include:

• Household exposure to infected blood or personal items.
• Asymptomatic adult carriers, nearly half of whom do not know they are infected.

Why the Birth Dose Matters

• Chronic infection risk is highest in infancy: A 90% risk of chronic HBV exists for babies infected in their first year.
• Long-term outcomes are severe: Chronic HBV leads to liver failure and cancer; 15–25% of those infected in childhood die prematurely.
• Effectiveness is proven: Universal vaccination has reduced childhood HBV cases by 95–99% since 1991.

Throughout its three-month period of data collection, the current ACIP found no evidence of harm from vaccination starting at birth.¹⁰ However, without a birth dose, the achieved gains are threatened.

Summary

A birth dose of the hepatitis B vaccine remains one of the most effective public health interventions ever implemented in the United States.

Given the high risk of chronic infection in infected infants, the vulnerability of families with limited perinatal care, and the overwhelming success of universal vaccination, the recent ACIP policy reversal raises substantial concerns. The coming years will reveal whether individualized decision-making can match the protective power of a universal approach—but decades of evidence suggest it cannot.

References

1. Mayo Clinic. (2024). Hepatitis B. Retrieved December 8, 2025, from https://www.mayoclinic.org/diseases-conditions/hepatitis-b/symptoms-causes/syc-20366802.
2. Page S, Experts urge continued hepatitis B vaccine birth doses for newborns. Retrieved December 8, 2025, from https://www.michiganmedicine.org/health-lab/experts-urge-continued-hepatitis-b-vaccine-birth-doses-newborns.
3. Ding Y, Sun X, Xu Y, Yang L, Zhang Y, Shen Q. (2020). Association between income and hepatitis B seroprevalence: A systematic review and meta-analysis. Hepatitis Monthly. 20(10); e104675. Retrieved December 8, 2025, from https://brieflands.com/journals/hepatmon/articles/104675.
4. Centers for Disease Control and Prevention. (2025). ACIP Recommends Individual-Based Decision-Making for Hepatitis B Vaccine for Infants Born to Women Who Test Negative for the Virus. Retrieved December 8, 2025, from https://www.cdc.gov/media/releases/2025/2025-acip-recommends-individual-based-decision-making-for-hepatitis-b-vaccine-for-infants-born-to-women.html.
5. American Public Health Association. APHA joins GW and dozens of public health and policy experts urging the CDC to maintain universal newborn hepatitis B vaccination. Retrieved December 8, 2025, from https://www.apha.org/news-and-media/news-releases/apha-news-releases/public-health-and-policy-experts-urge-the-cdc-to-maintain-universal-newborn-hepatitis-b-vaccination.
6. Sutfin L. (2025). MDHHS Issues Statement on Hepatitis B Vaccine. Retrieved December 9, 2025, from https://www.michigan.gov/mdhhs/inside-mdhhs/newsroom/2025/12/05/hep-b.
7. Jenco M. (2025). AAP: Changes to hepatitis B recommendations ‘irresponsible and purposely misleading.’ Retrieved December 9, 2025, from https://publications.aap.org/aapnews/news/33915/AAP-Changes-to-hepatitis-B-recommendations?autologincheck=redirected.
8. American Academy of Family Physicians. (2025). AAFP Supports Maintaining Universal Hepatitis B Vaccination at Birth. Retrieved December 12, 2025, from https://www.aafp.org/news/media-center/statements/aafp-supports-maintaining-universal-hepatitis-b-vaccination-at-birth.html.
9. Ibrahim MA. (1985). Epidemiology and Health Policy. Rockville, MD: Aspen Systems Corp.
10. Gilmour D, CNN anchor stunned as CDC vaccine advisor warns newborn jabs rollback ‘Wasn’t based on data.’ Retrieved December 10, 2025, from https://www.yahoo.com/news/articles/cnn-anchor-stunned-cdc-vaccine-173915350.html.

Updated 12/15/2025